PPARA and cancer: Treatment with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, attenuates cisplatin cytotoxicity in A549 cells through the activation of the aryl hydrocarbon receptor–Nrf2 axis, which is related to the increased expression of antioxidant enzymes and enhanced GSH synthesis, which protects cancer cells [21].